We currently have two programs in development. Our most advanced asset is at the preclinical developement stage targeting peripherally restricted and selective HDAC6i for Charcot-Marie-Touth (CMT) rare disease and other axonopathies (e.g. Chemotherapy-induced peripheral neuropathies). Our second program is focusing on brain penetrant and selective HDAC6i, currently in lead optimization stage, for the treatment of neurodegenerative diseases, such as Amyotrophic lateral sclerosis or Frontotemporal dementia. With a "Pipeline-in-a-product" approach, our drug discovery engine is poised to deliver multiple drug candidates with peripheral or central actions.